98349-24-7

Basic information

• Product Name: Ethyl 2,4,5-trifluorobenzoylacetate
• Synonyms: 3-OXO-3-(2,4,5-TRIFLUORO-PHENYL)-PROPIONIC ACID ETHYL ESTER;ETHYL 3-(2,4,5-TRIFLUOROPHENYL)-3-OXOPROPANOATE;ETHYL 3-OXO-3-(2,4,5-TRIFLUOROPHENYL)PROPANOATE;ETHYL 2,4,5-TRIFLUOROBENZOYLACETATE;2,4,5-Triflurobenzoflacetate;ETHYL 3-OXO-3(2,4,5-TRIFLUOROPHENYL) PROPIONATE;Ethyl (2,4,5-trifluorobenzoyl)acetate, Ethyl 2-(2,4,5-trifluorobenzoyl)ethanoate;ethyl 2,4,5-trifluorobenzoylacetat
• CAS NO: 98349-24-7
• Molecular Formula: C₁₁H₉F₃O₃
• Molecular Weight: 246.18
• Product Categories: Phenyls & Phenyl-Het;Benzoic acid;Phenyls & Phenyl-Het
• Mol File: 98349-24-7.mol

Chemical Properties

• Melting Point: 66-68°C
• Boiling Point: 283.1 °C at 760 mmHg
• Flash Point: 121.2 °C
• Appearance: off-white crystall powder
• Density: 1.319 g/cm³
• Vapor Pressure: 0.00322mmHg at 25°C
• Refractive Index: 1.468
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: soluble in Toluene
• PKA: 10.26±0.50(Predicted)
• CAS DataBase Reference: Ethyl 2,4,5-trifluorobenzoylacetate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 2,4,5-trifluorobenzoylacetate(98349-24-7)
• EPA Substance Registry System: Ethyl 2,4,5-trifluorobenzoylacetate(98349-24-7)

Safety Data

• Hazard Codes: C,Xi,T
• Statements: 36/37/38
• Safety Statements: 26-36/37/39
• RIDADR: UN2811 6.1
• HazardClass: IRRITANT
• Hazardous Substances Data: 98349-24-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Ethyl 2,4,5-trifluorobenzoylacetate is used as a key intermediate in the synthesis of aminopyrrolidinyl)quinolinecarboxylates, which are compounds with significant antitumor activities. These compounds have the potential to be developed into effective cancer therapeutics, offering new treatment options for patients.
Used in Agrochemical Industry:
Ethyl 2,4,5-trifluorobenzoylacetate can also be utilized in the development of agrochemicals, such as pesticides and herbicides. The trifluorophenyl moiety in this compound may impart specific biological activities, making it a valuable building block for the creation of novel and effective agrochemicals.

InChI:InChI=1/C11H9F3O3/c1-2-17-11(16)5-10(15)6-3-8(13)9(14)4-7(6)12/h3-4H,2,5H2,1H3

Upstream product

• 1071-46-1 hydrogen ethyl malonate 
• 88419-56-1 2,4,5-trifluorobenzoyl chloride 
• 141-97-9 ethyl acetoacetate 
• 104600-15-9 (2,4,5-trifluorobenzoyl)propanedioic acid, diethyl ester 
• 129322-83-4 2',4',5'-trifluoroacetophenone 
• 105-58-8 Diethyl carbonate 
• 367-23-7 1,2,4-trifluorobenzene 
• 98349-22-5 2,4,5-trifluorobenzonitrile 
• 327-52-6 1-bromo-2,4,5-trifluorobenzene 
• 446-17-3 2,4,5-trifluorobenzoic acid 
• 6148-64-7 ethyl potassium malonate 
• 119209-55-1 propanedioic acid monoethyl ester dilithium salt 

Downstream Products

• 98349-25-8 ethyl 1-cyclopropyl-6,7-difluoro-4-oxo-1,4-dihydro-quinoline-3-carboxylate 
• 101799-76-2 3-Cyclopropylamino-2-(2,4,5-trifluorbenzoyl)acrylsaeure-ethylester 
• 166816-31-5 ethyl 2-(2,4,5-trifluorobenzoyl)-3-(isoxazol-3-ylamino)acrylate 
• 138998-46-6 ethyl 3-(dimethylamino)-2-(2,4,5-trifluorobenzoyl)prop-2-enoate 
• 98105-99-8 sarafloxacin 

Relevant articles and documents

Refining method of ciprofloxacin and meglumine hydrochloride thereof

The invention provides a preparation process of ciprofloxacin and meglumine thereof. The intermediate product DLSX07 is stirred at Branson ° C. 20% minutes and then sonicated until the solution is cloudy, stirred at room temperature for a period 30s, stirred at room temperature 3h, cooled and slowly added to distilled water, and filtered through suction filtration and filter cake vacuum drying to obtain a pale yellow powder, and 4% the KOH mixture is subjected to ultrasonic treatment 40 - 50 °C. 1. The process is performed by stirring 5h. NCS .t. The solution is cloudy. LC-MS / MS detection powder is deltafloxacin, distilled water is added, and meglumine is mixed to obtain a deltafloxacin meglumine salt. By optimizing the preparation process, the use of the organic solvent is reduced, the reaction time is shortened, and the ice bath and the addition of the interface carrier material contribute to the improvement of the yield.

Preparation method and purification method of 2, 4, 5-trifluorobenzoyl ethyl acetate

The invention relates to the field of organic synthesis, in particular to a preparation method and a purification method of 2, 4, 5-trifluorobenzoyl ethyl acetate. The method comprises the following steps: carrying out acylating chlorination reaction on 2, 4, 5-trifluorobenzoic acid and acyl chloride, continuously reacting with ethyl acetoacetate in a weakly alkaline solution to obtain an intermediate product, and heating the intermediate product to remove acetyl, thereby obtaining the 2, 4, 5-trifluorobenzoyl ethyl acetate. A one-pot method is adopted, operation is easy, only a small amount of waste residues are generated in the reaction process, and intramolecular hydrogen bonds and chelate structures are effectively avoided. The solvent can be recycled and reused, the method is economical, environmentally friendly, high in conversion rate and beneficial to industrial production, the invention further provides a purification method, impurities in the reaction process are effectivelyremoved, and the product with the purity larger than 99.5% is prepared.

Quinolone dimers as potential antibacterial agents

A series of novel 6-fluoro1,4-dihydro-4-oxo-3-quinoline carboxylic acid dimers (34-37), were synthesized as potential antibacterial agents from commercially available fluoro benzoic acids.

9-(HETEROARYL)-ISOTHIAZOLO[5,4-B]QUINOLINE-3,4-DIONES AND RELATED COMPOUNDS AS ANTI-INFECTIVE AGENTS

The invention provides compounds and salts of Formula (I) and Formula (II); which possess antimicrobial activity. The invention also provides novel synthetic intermediates useful in making compounds of Formula (I) and Formula (II). The variables R2, R3, R5, R6, R7, A8 and R9 are defined herein. Certain compounds of Formula (I) and Formula (II) disclosed herein are potent and/or selective inhibitors of bacterial DNA synthesis and bacterial replication. The invention also provides antimicrobial compositions, including pharmaceutical compositions, containing one or more compounds of Formula (I) or Formula (II) and one or more carriers, excipients, or diluents. Such compositions may contain a compound of Formula (I) or Formula (II) as the only active agent or may contain a combination of a compound of Formula (I) or Formula (II) and one or more other active agents. The invention also provides methods for treating microbial infections in animals.

PREPARATION OF PYRIDONECARBOXYLIC ACID ANTIBACTERIALS

A process for making 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, and therapeutically acceptable salts thereof, and intermediates used in the process are disclosed.

Chlorination at the 8-position of a functionalized quinolone and the synthesis of quinolone antibiotic ABT-492

The total synthesis of quinolone antibiotic ABT-492 has been achieved in 67% yield over nine steps from 2,4,5-trifluorobenzoic acid. The highlights of this synthesis include a novel chemoselective chlorination at the 8-position of a highly elaborated quinolone core. In addition, a Lewis acid promoted cyclization reaction to form the quinolone heterocycle was developed which was incorporated into a one-pot, three-step cyclization/coupling/protection sequence that proceeds in 93% yield.

A prodrug approach toward the development of water soluble fluoroquinolones and structure-activity relationships of quinoline-3-carboxylic acids

A fluoroquinolone prodrug, PA2808, was prepared and shown to convert to the highly active parent drug PA2789. In vitro and in vivo activation of PA2808 by alkaline phosphatase was demonstrated using disk diffusion and rat lung infection models. The water solubility of PA2808 showed a marked increase compared to PA2789 over a pH range suitable for aerosol drug delivery. A total of 48 analogues based on PA2789 were prepared and screened against a panel of Gram-positive and Gram-negative pathogens. Incorporating a cyclopropane-fused pyrrolidine (amine g) at C-7 resulted in some of the most active analogues.

Synthesis and structure-activity relationships of novel 7-substituted 1,4-dihydro-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acids as antitumor agents. Part 1

In an attempt to search for clinically useful antitumor agents, we have discovered that a series of 1,7-disubstituted-6-fluoro-1,4-dihydro-4-oxo-1,8-naphthyridine-3-carboxylic acids possessed moderate cytotoxic activity. We investigated the structure-acti

Glycosylation of fluoroquinolones through direct and oxygenated polymethylene linkages as a sugar-mediated active transport system for antimicrobials

We report herein the synthesis and biological testing of several glycosylated derivatives of some fluoroquinolone antibiotics. In particular, we have prepared several glycosylated derivatives of ciprofloxacin (2) in which the carbohydrate units are linked

Use of tetrabenzo[a,c,g,i]fluorene as an anchor group for the solid/solution phase synthesis of the quinolone antibacterial, ciprofioxacin

The affinity of tetrabenzo[a,c,g,i]fluorene (Tbf) for charcoal has been applied successfully to provide an alternative to existing solid phase synthesis methodology. In a synthesis of the quinolone antibacterial, Ciprofloxacin, traditional solution phase synthesis has been coupled with efficient pseudo-solid phase purification.